Drug Database
Back to search

Poland· PL-100452882

Ovamex

A ganirelix product containing ganirelixum, registered in Poland by Theramex Ireland Limited. The same ATC class is registered in 17 of our 19 countries.

ATC H01CC01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOvamexATCH01CC01REGISTER NO.PL-100452882PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ganirelixumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ganirelix is registered in 17 of 19 countries.

Countries holding a registration under ATC H01CC01 (ganirelix), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search ganirelix products by name

Ganirelix · ATC H01CC01

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Ganirelixum
Manufacturer
Theramex Ireland Limited
Country
Poland (PL)
ATC code
H01CC01
ATC class
Ganirelix
Defined daily dose
0.25 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05060632509246

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for ganirelix.

Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ganirelix against other medicinesHow interaction checks work

Ganirelix · interactions on record

7 records

  • 7 moderate

Most severe, free to view

  • Chorionic gonadotrophinG03GA01moderate
  • Menotropin HMGG03GA02moderate
  • UrofollitropinG03GA04moderate
  • GonadorelinH01CA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ganirelix in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ganirelix products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Ganirelix Astro, Ganirelix Theramex
  • Belgium · Fyremadel, Ovamex
  • Bulgaria · Ganirelix Theramex
  • Czechia · Fyremadel
  • Germany · Fyremadel, Ganiran
  • Denmark · Fyremadel, Ganirelix Orifarm
  • Estonia · Ganirelix Theramex
  • Spain · Astarté, Fyremadel
  • Finland · Fyremadel, Ganirelix Orifarm
  • France · Fyremadel, Ganirelix Eg
  • United Kingdom (Northern Ireland) · Fyremadel
  • Greece · Fyremadel, Ovamex
  • Croatia · Ganireliks Theramex
  • Hungary · Ganirelix Theramex
  • Iceland · Ganirelix, Ganirelix Gedeon Richter
  • Italy · Fyremadel, Ovamex
  • Liechtenstein · Ganirelix, Ganirelix Gedeon Richter
  • Lithuania · Ganirelix Theramex
  • Latvia · Ganirelix Theramex
  • Netherlands · Fyremadel, Ganirelix Fagron
  • Norway · Fyremadel, Ganirelix
  • Portugal · Astarté, Fyremadel
  • Sweden · Fyremadel, Ganirelix Orifarm
  • Slovenia · Ganireliks Theramex
  • Slovakia · Fyremadel, Ganirelix Theramex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/febd9f87-21d8-4ce1-885b-a8ff6f20430d
GET /v1/drugs/febd9f87-21d8-4ce1-885b-a8ff6f20430d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "0,25 mg/0,5 ml",
  "packaging": "05060632509246 ¦ Rpz ¦ 146348\n1 amp.-strzyk. 0,5 ml",
  "substance": "Ganirelixi acetas 0,25 mg/0,5 ml",
  "common_name": "Ganirelixum",
  "pl_product_id": "100452882",
  "pozwolenie_nr": "27248",
  "auth_procedure": "DCP",
  "authorisation_validity": "2027-08-04"
}
API referenceMCP serverPlans

See everything about ganirelix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console